| Management target | Revenue 15.0% FY27 |
|---|
| Revenue growth | 23.1% YoY consolidated growth; base business grew 18%. |
|---|---|
| Margins | EBITDA margins targeted at 21-22% despite supply chain headwinds. |
| Demand visibility | Strong visibility in India and US respiratory/oncology segments. |
| Management confidence | Confident, focusing on innovation pipeline and branded portfolio expansion. |
Growth
Base business grew 18% excluding deferred income; India outperformed IPM at 15.5% growth while US grew 19.8%.
Outlook
Management maintains FY27 EBITDA margin guidance of 21-22% and expects 12-15% India growth.
Risks
Elevated API and logistics costs due to geopolitical situations threaten near-term gross margin stability.
Earnings Call Transcript filed with NSE, NSE: GLENMARK. Summary written with AI assistance from the document.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,293.50
- Market cap
- ₹64,728 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.0×Sector 47.4×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 20.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.